Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling
Authors:
Open Access
- 5 February 2025
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 33 (4) , 1659-1673
Abstract
No abstract availableKeywords
Funding Information
- General Research Fund of Shanghai Normal University (14119023, 14108219)
- University Grants Committee
- Li Ka Shing Foundation
- National Institutes of Health
- National Cancer Institute
- Terry Fox Foundation
This publication has 51 references indexed in Scilit:
- Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trialJournal of Cancer Research and Clinical Oncology, 2021
- Acquired Resistance to Immune Checkpoint InhibitorsCancer Cell, 2020
- Landscape and Dynamics of Single Immune Cells in Hepatocellular CarcinomaCell, 2019
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver CancerCancer Cell, 2019
- Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric CancerCell Reports, 2019
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009